Failure To Invest In Drug Repositioning Is Frustrating, Says EU Rare Disease Patients Group
Yann Le Cam, who heads the EU network of rare disease patient organizations, is calling for innovative solutions to support the 'repositioning' of existing and new medicines that could potentially treat orphan conditions but are not developed by companies due to business considerations.
You may also be interested in...
Draft proposals to improve EU-wide cooperation on health technology assessments, including mandatory joint clinical assessments, have won support from EFPIA, the European Federation of Pharmaceutical Industries and Associations.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.